Chieng Norman, Aaltonen Jaakko, Saville Dorothy, Rades Thomas
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Eur J Pharm Biopharm. 2009 Jan;71(1):47-54. doi: 10.1016/j.ejpb.2008.06.022. Epub 2008 Jul 3.
Co-milling of gamma-indomethacin and ranitidine hydrochloride form 2 at various weight ratios (1:2, 1:1 and 2:1) was investigated with a particular interest in the physicochemical properties and the stability of the milled mixed amorphous form. Co-milling was carried out using an oscillatory ball mill for various periods of time up to 60 min in a cold room (4 degrees C). The maximum temperature of the solid material was 42 degrees C during co-milling in a cold room. Results showed that both indomethacin and ranitidine hydrochloride were fully converted into the amorphous state after 60 min of co-milling. In contrast individually milled drugs remained partially crystalline after co-milling under the same conditions. During co-milling, the XRPD characteristic peaks of indomethacin were found to decrease faster than those of ranitidine hydrochloride. DSC results were in agreement with XRPD, and T(g)s of the fully converted amorphous mixtures of 29.3, 32.5 and 34.3 degrees C were measured for the 1:2, 1:1 and 2:1 mixtures, respectively. These T(g) values were in good agreement with the predicted T(g)s of the mixtures using the Gordon-Taylor equation. DRIFTS spectra of the co-milled amorphous samples showed peaks at 1610, 1679 and 1723 cm(-1), that were not present in the individually milled samples and that are indicative of an interaction at the carboxylic acid carbonyl (HO-C=O) and benzonyl amide (N=CO) of the indomethacin molecule with the aci-nitro (C=N) of ranitidine hydrochloride. Upon 30 days of storage, the 1:2 mixtures were found to crystallize; however, the amorphous 2:1 and 1:1 mixtures were stable when milled for 60 min and stored at 4 degrees C (for the 2:1 mixture) and at 4 and 25 degrees C (for the 1:1 mixture), respectively. Although XRPD, DSC and DRIFTS suggested an interaction between the two drugs, co-crystal formation was not observed between indomethacin and ranitidine hydrochloride.
研究了γ-吲哚美辛与盐酸雷尼替丁晶型2在不同重量比(1:2、1:1和2:1)下的共研磨情况,特别关注研磨后的混合无定形物的物理化学性质和稳定性。在冷室(4℃)中使用振荡球磨机进行共研磨,共研磨时间长达60分钟。在冷室中进行共研磨时,固体材料的最高温度为42℃。结果表明,共研磨60分钟后,吲哚美辛和盐酸雷尼替丁均完全转变为无定形状态。相比之下,在相同条件下共研磨后,单独研磨的药物仍部分结晶。在共研磨过程中,发现吲哚美辛的X射线粉末衍射(XRPD)特征峰比盐酸雷尼替丁的特征峰下降得更快。差示扫描量热法(DSC)结果与XRPD结果一致,对于1:2、1:1和2:1的混合物,完全转变的无定形混合物的玻璃化转变温度(Tg)分别为29.3℃、32.5℃和34.3℃。这些Tg值与使用戈登-泰勒方程预测的混合物Tg值非常吻合。共研磨无定形样品的漫反射红外傅里叶变换光谱(DRIFTS)在1610、1679和1723 cm⁻¹处出现峰,这些峰在单独研磨的样品中不存在,表明吲哚美辛分子的羧酸羰基(HO-C=O)和苯甲酰酰胺(N=CO)与盐酸雷尼替丁的酸式硝基(C=N)之间存在相互作用。储存30天后,发现1:2的混合物结晶;然而,无定形的2:1和1:1混合物在分别研磨60分钟并储存在4℃(对于2:1混合物)以及4℃和25℃(对于1:1混合物)时是稳定的。尽管XRPD、DSC和DRIFTS表明两种药物之间存在相互作用,但未观察到吲哚美辛与盐酸雷尼替丁之间形成共晶体。